Lipoprotein(a), abbreviated Lp(a), is structurally an LDL particle with a twist. It contains apolipoprotein B100 covalently linked, in a one-to-one molar ratio, to apolipoprotein(a), a glycoprotein whose gene sits on chromosome 6 and shares more than 80 percent structural homology with plasminogen, the key enzyme precursor of blood clot dissolution. Apolipoprotein(a) is built from repeated kringle domains, and one of them, kringle 4 type 2, is present in a variable number of copies, usually between 3 and more than 40. This copy number varies enormously between individuals and ancestry groups and is the major determinant of both the size of the particle and the concentration of Lp(a) in plasma: smaller isoforms are secreted more efficiently by hepatocytes, so people carrying fewer repeats tend to have higher circulating levels. The entire production process occurs in the liver, where apo(a) and apoB are secreted separately and assembled into mature Lp(a) particles outside the cell.

The scientific history of Lp(a) is a story of enthusiasm, disappointment, and redemption. After observational studies in the late 1980s linked plasma levels to coronary heart disease, early prospective trials produced discordant results, and because no diet or drug could reliably lower the particle, interest waned for roughly two decades. That picture changed dramatically with population-based studies, meta-analyses, genome-wide association studies, and Mendelian randomization analyses, which together established Lp(a) as a strong, independent, and genetically determined causal risk factor for atherosclerotic cardiovascular disease. Plasma Lp(a) measurement now reclassifies the risk category of approximately 40 percent of primary prevention patients who sit in the intermediate band of the Framingham risk score, and recent guidelines recommend widespread testing. Values above 50 mg/dL, or 125 nmol/L, are conventionally considered elevated; roughly 15 to 20 percent of people worldwide exceed this threshold, and the population distribution is strongly skewed, ranging from less than 0.2 to more than 200 mg/dL.

The concept of residual cardiovascular risk is central to the review’s argument. Even when blood pressure, LDL cholesterol, blood glucose, obesity, and smoking are treated to the best standards of care, a substantial probability of major adverse cardiovascular events remains. The evidence is striking. In the PRIME study, which followed 9,649 men aged 50 to 59 for ten years, treated hypertensive patients had a 50 percent higher relative risk of major cardiovascular events after adjustment for concurrent risk factors. In the Framingham Offspring Cohort, treated hypertensive patients whose blood pressure was below 140/90 mm Hg still carried a 50 percent higher risk of cardiovascular events than untreated subjects with comparable readings. On the lipid side, long-term reassessments of early statin trials show a residual risk of approximately 30 percent, and even trials of the most potent PCSK9 inhibitors, which drove LDL cholesterol to a median below 30 mg/dL, could not normalize cardiovascular risk. A recent participant-level meta-analysis demonstrated that effective LDL reduction does not offset Lp(a)-related risk: participants with Lp(a) above 50 mg/dL and LDL below 77 mg/dL still had a 38 percent greater risk than patients with lower Lp(a) levels.

What makes Lp(a) especially relevant to kidney disease is that the kidney itself appears to be a major site of Lp(a) clearance. Clinical studies consistently show that plasma Lp(a) rises progressively as glomerular filtration rate falls, and the review’s authors contributed their own evidence: in 417 patients with arterial hypertension, 160 of whom had hypertensive nephroangiosclerosis with creatinine clearance between 30 and 89 mL/min/1.73 m², Lp(a) levels were significantly higher in those with renal involvement, correlated inversely with creatinine clearance, and were associated with more prevalent coronary, cerebrovascular, and peripheral artery disease. Notably, urinary albumin losses did not correlate with Lp(a) levels and apo(a) phenotype distribution was comparable across levels of kidney function, suggesting that kidney damage itself, rather than altered isoform expression, drives the increase. Stable isotope turnover studies and urinary apo(a) clearance studies support the conclusion that elevated Lp(a) in chronic kidney disease reflects reduced renal clearance rather than increased hepatic production.

Prospective cohort data now confirm that this biochemical elevation translates into clinical harm. In the Chronic Renal Insufficiency Cohort study, 3,744 participants followed for 7.5 years showed that those in the highest quartile of Lp(a), above 61.3 mg/dL, had a 49 percent higher risk of myocardial infarction and a 28 percent higher risk of death. The German Chronic Kidney Disease study, which followed 5,043 subjects for 6.5 years, found that each 10 mg/dL increase in Lp(a) raised cardiovascular disease risk by 6.5 percent, with risk climbing more than 30 percent in subjects above 70 mg/dL regardless of traditional risk factors. A systematic review of 15 studies encompassing 12,260 participants with kidney disease confirmed that high Lp(a) independently predicts cardiovascular events and death, and data from the China Renal Data System, covering more than 50,000 participants, linked rising Lp(a) to both progression of renal failure and cardiovascular mortality. The particle is also entwined with calcific aortic valve disease, which frequently accompanies advanced kidney disease, although MESA study data on 6,346 subjects found the association between valve calcification and kidney dysfunction occurred independently of Lp(a) levels.

The dialysis and transplantation literature provides a natural experiment that strengthens the causal interpretation. Patients on hemodialysis have higher Lp(a) than healthy subjects and patients with early kidney disease, and peritoneal dialysis patients show elevations independent of apo(a) isoform size. Crucially, neither hemodialysis nor peritoneal dialysis lowers Lp(a), whereas renal transplantation significantly reduces it, a rapid change consistent with the restoration of renal clearance. In nephrotic syndrome, where heavy urinary protein wasting raises Lp(a) independently of filtration rate, levels normalize after remission of the causative condition, likely reflecting increased hepatic synthesis rather than impaired catabolism. Together these observations justify repeated Lp(a) measurements during the course of progressive kidney disease, since levels fluctuate with inflammatory states and changes in treatment even though they are largely stable over time in the general population.

The therapeutic landscape is changing rapidly. Traditional lipid-lowering drugs have negligible effects on Lp(a), and dietary interventions are unpredictable at best, although replacing saturated fatty acids with unsaturated fats and long-chain carbohydrates produces small reductions. The PCSK9 inhibitors evolocumab and alirocumab lower Lp(a) by only about 27 and 23 percent respectively, from baseline levels that were mostly well below risk thresholds. The new generation of agents is different. Pelacarsen, an antisense oligonucleotide delivered to hepatocytes via the asialoglycoprotein receptor, degrades LPA mRNA and reduced Lp(a) by 80 percent at a dose of 20 mg weekly over six months. Small interfering RNAs conjugated with N-acetyl-galactosamine, including olpasiran, zerlasiran, and lepodisiran, harness the RNA-induced silencing complex to the same end: olpasiran achieved placebo-adjusted reductions of 97 percent, zerlasiran 95 percent with a single 450 mg dose, and lepodisiran 94 percent with 400 mg. Muvalaplin, an oral small molecule that blocks the kringle 4-mediated interaction between apo(a) and apoB, reduced Lp(a) by 86 percent at 240 mg per day over three months. Phase 3 outcome trials such as Lp(a)HORIZON, OCEAN(a), and ACCLAIM-Lp(a) are now testing whether these dramatic biochemical reductions translate into fewer cardiovascular events.

There is, however, a critical caveat for the kidney community: every trial of these investigational drugs excluded patients with advanced chronic kidney disease or on dialysis, so efficacy, dosing, and long-term safety in renal patients remain unknown and cannot be extrapolated. In the meantime, the review’s authors emphasize that rigorous application of proven preventive measures remains essential, including smoking cessation, salt restriction, exercise, blood pressure targets below 130/80 mm Hg with renin-angiotensin system inhibitors, glycated hemoglobin below 7.0 percent, SGLT2 inhibitors, GLP-1 receptor agonists, finerenone, and intensive lipid lowering to LDL below 55 mg/dL using statins, ezetimibe, and PCSK9 inhibitors as needed. For selected high-risk patients with elevated Lp(a), lipoprotein apheresis offers an existing, if cumbersome, option: retrospective series report reductions from a mean of 138 mg/dL to 51 mg/dL with a 94 percent reduction in major cardiovascular events over four years, and in nine hemodialysis patients undergoing combined apheresis, median Lp(a) fell from 242.7 to 64.2 nmol/L with a 57 percent reduction in adverse cardiac and vascular events over four years.

A landmark Mendelian randomization analysis adds a note of scientific caution: genetically predicted lifelong differences in Lp(a) correspond to an estimated 6 percent decrease in atherosclerotic cardiovascular disease odds for every 10 mg/dL reduction, but such estimates cannot be directly translated into the expected effect of short-term pharmacological lowering, and meaningful clinical benefit would likely require reductions greater than 50 mg/dL. Still, with new therapies capable of cutting Lp(a) by up to 90 percent from baseline, the potential is enormous. If ongoing trials demonstrate that profound Lp(a) reduction lowers residual cardiovascular risk, and if dedicated studies in patients with kidney disease follow, Lp(a) could be transformed from a passive risk marker into a primary therapeutic target for one of the most vulnerable populations in cardiovascular medicine.

Subject of Research: The role of lipoprotein(a) in residual cardiovascular risk among patients with chronic kidney disease and emerging Lp(a)-lowering therapies

Article Title: Lipoprotein(a): a potential target for the reduction of residual cardiovascular risk in patients with chronic kidney disease

Article References: Sechi, L. A., Bulfone, L., Vacca, A., Comand, J., Marcante, S., Brosolo, G., Pagano, C., & Catena, C. (2026). Lipoprotein(a): a potential target for the reduction of residual cardiovascular risk in patients with chronic kidney disease. Frontiers in Nephrology, 6, Article 1950030. https://doi.org/10.3389/fneph.2026.1950030

Image Credits: AI Generated

DOI: 10.3389/fneph.2026.1950030

Keywords: lipoprotein(a), chronic kidney disease, residual cardiovascular risk, atherosclerotic cardiovascular disease, antisense oligonucleotides, small interfering RNA, pelacarsen, olpasiran, muvalaplin, lipoprotein apheresis, renal clearance, cardiovascular prevention

The biology at the heart of the study begins at the neuromuscular junction, the microscopic relay where motor neurons hand their signals to muscle fibers. In the most common form of myasthenia gravis, autoantibodies bind the acetylcholine receptor clustered on the muscle side of this synapse. Those antibodies do more than simply block the receptor; many of them recruit the complement system, an ancient arm of immune defense designed to punch holes in the membranes of invading microbes. When complement is triggered at the synapse, it assembles the membrane attack complex, a pore-forming structure that tears into the postsynaptic membrane. The result is destruction of the synaptic folds, loss of acetylcholine receptors, inflammatory infiltration of macrophages into the endplate region, and ultimately a failure of neuromuscular transmission that patients experience as drooping eyelids, double vision, and life-threatening weakness of the muscles that control breathing and swallowing.

Complement activation follows a strictly ordered cascade, and C3 sits at its pivotal center. All major activation pathways converge on this protein, which, once cleaved, seeds opsonization of target tissue, amplifies the response through amplification loops, and drives the terminal assembly of the membrane attack complex. This convergence point has long made C3 an attractive therapeutic target, and drugs that inhibit it are already reshaping the treatment landscape of several complement-mediated disorders. What the new study adds is a direct test, in a rigorous animal model, of whether near-total elimination of circulating C3, achieved not with a blocking antibody but by silencing the gene that produces the protein in the liver, can prevent the structural and functional damage of myasthenia gravis during its acute phase.

The experimental approach relied on small interfering RNA, short synthetic RNA molecules that hijack the cell’s own RNA-induced silencing complex to degrade a specific messenger RNA before it can be translated into protein. To make sure the siRNA reached its destination, the researchers equipped it with a triantennary N-acetylgalactosamine ligand, a chemical handle that binds with high affinity to the asialoglycoprotein receptor abundantly displayed on hepatocytes. This GalNAc-targeting technology, which has already transformed the delivery of other liver-directed RNA therapies, allowed the compound to be administered by simple subcutaneous injection rather than intravenous infusion. Female Lewis rats received the C3-siRNA at different dosages before the researchers induced disease by passive transfer, injecting a monoclonal antibody directed against the acetylcholine receptor, a model known as passive transfer myasthenia gravis that reproduces the acute complement-mediated attack on the synapse without requiring the animals to mount their own autoimmune response.

The degree of target engagement was remarkable. Two administrations of the C3-siRNA at 30 milligrams per kilogram, spaced one week apart, reduced plasma C3 levels by more than 98 percent, pushing them below the detection limit of the assay. Against this near-total depletion of the central complement component, the researchers then challenged the animals with the pathogenic anti-receptor antibody and tracked the consequences with an unusually comprehensive battery of readouts: clinical scoring of weakness, direct measurements of muscle strength, electromyographic assessment of transmission failure at the junction, quantification of total and functional acetylcholine receptor levels in muscle, histological analysis of macrophage infiltration and sectional necrosis in the motor endplate region, and immunostaining for complement activation products deposited at the synapse.

The protective effect was evident across essentially every parameter measured. Treated animals showed significantly reduced deposition of the membrane attack complex at the neuromuscular junction, indicating that the terminal complement attack had been blunted. The characteristic tissue damage of the disease was correspondingly diminished: sectional necrosis within the endplate region was reduced, and the influx of macrophages that normally follows complement-mediated injury was attenuated. Skeletal muscle C3 messenger RNA, which is upregulated locally during the disease process, rose less in the treated animals. Importantly, the therapy partially preserved functional acetylcholine receptor levels, meaning that the receptors remaining at the synapse were better able to do their job of transmitting neuronal signals to the muscle. The structural preservation translated into function: muscle strength assessments and electromyography showed that the development of muscle weakness was effectively attenuated in the treated rats compared with controls.

Perhaps the most scientifically provocative observation came from what the treatment did not achieve. Despite the near-total elimination of C3 from the plasma, low levels of C3 activation products and membrane attack complex were still detectable specifically at the neuromuscular junction. This residual deposition is more than a technical footnote. It demonstrates that even a vanishingly small amount of circulating C3 is sufficient to sustain some degree of complement activation at the inflamed synapse, where local amplification mechanisms and the intense concentration of activating antibodies can make the most of scarce substrate. The authors interpret this as evidence of the powerful pathogenic potency of C3 in acetylcholine receptor-positive myasthenia gravis: the protein is so effective a driver of tissue injury that even trace quantities can leave a molecular fingerprint of damage at the junction.

That observation carries practical implications for how complement-targeted therapies might be deployed in patients. If near-complete suppression of plasma C3 leaves residual terminal pathway activity at the neuromuscular junction, then the therapeutic goal in myasthenia gravis may need to be either maximally deep C3 suppression, combination approaches that pair hepatic silencing with additional inhibition at the tissue level, or careful biomarker monitoring of complement deposition at the synapse itself rather than relying solely on systemic measures. At the same time, the study shows that the degree of protection achieved with hepatic silencing alone was already substantial, preserving receptor function and blunting weakness in the acute disease phase, which supports the idea that C3 silencing could serve as an adjunctive therapy layered onto existing immunosuppressive regimens rather than replacing them outright.

The work also illustrates how the tools of molecular medicine are being repurposed for organ-specific immunology. Rather than designing a protein drug to neutralize C3 in the bloodstream, the team used a GalNAc-conjugated siRNA to instruct the liver itself to stop making the protein, achieving durable, deep, and convenient subcutaneously delivered target reduction. This strategy builds on the broader success of RNA interference therapeutics in hepatic targets and suggests that complement proteins synthesized primarily by the liver are well suited to this modality. For a disease like myasthenia gravis, where chronic immunosuppression carries significant long-term burdens and where existing complement inhibitors require frequent intravenous administration, a long-acting subcutaneous gene-silencing approach could meaningfully change the treatment calculus, although the authors are careful to frame the current results as preclinical support for a potential adjunctive strategy rather than a validated therapy.

As with any animal study, the path from Lewis rats to patients runs through the usual gauntlet of safety, dosing, and clinical trial design, and the passive transfer model captures the acute effector phase of the disease rather than the full chronic autoimmune process that unfolds in patients. Nevertheless, the study delivers a clear and technically rigorous message: C3 is a dominant and remarkably potent driver of the complement-mediated destruction of the neuromuscular junction in antibody-positive myasthenia gravis, silencing its hepatic production protects receptor levels, synaptic architecture, and muscle function, and even the faint residual complement activity that survives near-total depletion underscores how aggressively this pathway must be restrained. For a disease in which the immune system’s own microbial-killing machinery turns against the synapse, teaching the liver to hold that machinery back may prove to be one of the more consequential therapeutic ideas to emerge from complement research in recent years.

Subject of Research: Complement C3 gene silencing as a therapy for complement-mediated neuromuscular junction damage in myasthenia gravis

Article Title: C3 complement silencing prevents acetylcholine receptor loss and reduces complement activation in the rat passive transfer myasthenia gravis model

Article References: Schöttler, A. K., Mané-Damas, M., Arets, B., Peng, S., Molenaar, P. C., De Baets, M. H., Claessen, S. M. H., Barbour, T., Richardson, E., Eyerman, D. J., Scheibler, L., Losen, M., & Martinez-Martinez, P. (2026). C3 complement silencing prevents acetylcholine receptor loss and reduces complement activation in the rat passive transfer myasthenia gravis model. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08832-5

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08832-5

Keywords: myasthenia gravis, complement C3, neuromuscular junction, small interfering RNA, GalNAc delivery, membrane attack complex, acetylcholine receptor, passive transfer model, complement inhibition, gene silencing, autoimmune disease, Lewis rats